Key result
Loxl2 inhibitor Simtuzumab prevents cardiac dysfunction and fibrosis in preclinical LMNA-associated dilated cardiomyopathy.
Why the study?
Does Simtuzumab prevent cardiac dysfunction and fibrosis in LMNA mutation-induced dilated cardiomyopathy preclinical models?
Does Simtuzumab prevent cardiac dysfunction and fibrosis in LMNA mutation-induced dilated cardiomyopathy preclinical models?
Inhibition of Loxl2 by Simtuzumab attenuates extracellular matrix remodeling and preserves cardiac function in preclinical models of LMNA mutation-induced dilated cardiomyopathy, suggesting a potential novel therapeutic strategy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Loxl2 inhibition merits testing in LMNA cardiomyopathy; hypothesis-generating in preclinical models and leaves open clinical translation.
BACKGROUND: Dilated cardiomyopathy caused by LMNA mutations is a severe cardiac condition marked by arrhythmias, contractile dysfunction, and excessive myocardial fibrosis, which collectively impair left ventricular function and increase the risk of heart failure. Although the disease has been well characterized, a lack of insight into the pathogenesis has impeded the development of therapies. METHODS: Here, we employed human induced pluripotent stem cells (hiPSCs) derived from a patient carrying a LMNA point mutation (c.665A>C, p.His222Pro), alongside a murine model carrying the same mutation, to investigate the functional and molecular abnormalities driving dilated cardiomyopathy. RESULTS: We demonstrated that LMNA patient-derived cardiomyocytes and engineered heart tissues exhibited elevated diastolic calcium levels and reduced sensitivity to external calcium, respectively, as well as hypocontractility. These cells also displayed nuclear shape abnormalities in 2-dimensional and 3-dimensional, a hallmark of LMNA -associated dilated cardiomyopathy, associated with disrupted chromosome spatial organization and altered gene expression profiles. Transcriptomic analysis revealed dysregulation of extracellular matrix remodeling and significant upregulation of Loxl2 in mutated hiPSC–cardiomyocytes, hiPSC–engineered heart tissues, and mice. Treatment with Simtuzumab, a Loxl2 inhibitor, effectively prevented cardiac dysfunction and fibrosis in vivo. CONCLUSIONS: Taken together, our findings underscore the crucial role of Loxl2 as a therapeutic target and suggest that its inhibition could be a promising strategy to preserve cardiac function in LMNA -associated dilated cardiomyopathy.
Kervella et al. (2026) studied LMNA Mutation-Induced Dilated Cardiomyopathy (n=7). Simtuzumab vs. Untreated / PBS was evaluated on Cardiac function (fractional shortening, ejection fraction, left ventricular end-diastolic dimension) and cardiac fibrosis. Treatment with the Loxl2 inhibitor Simtuzumab effectively prevented cardiac dysfunction and fibrosis in human induced pluripotent stem cells and mice with LMNA-associated dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: